Geneva, March 23 -- International Clinical Trials Registry received information related to the study (NCT07462533) titled 'Assess Efficacy of a Nanodiamond Periprocedural Skin Care Regimen for Ablative Resurfacing' on March 5.

Study Type: Interventional

Study Design: Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Diagnostic. Masking: None (Open Label).

Primary Sponsor: Goldman, Butterwick, Fitzpatrick and Groff

Condition: Skin Laxity

Intervention: Drug: Pavise Serum Drug: Sham Comparator

Recruitment Status: Not recruiting

Phase: Phase 2

Date of First Enrollment: March 20, 2026

Target Sample Size: 8

To know more, visit https://clinicaltrials.gov/study/NCT07462533

Published by HT Digital ...